Flibanzerin

Flibanzerin
(IUPAC) ime
	1-(24-[3-(trifluorometil)fenil]piperazin-1-il}etil)-1,3-dihidro-2H-benzimidazol-2-on
Klinički podaci
Identifikatori
CAS broj	167933-07-5
ATC kod	nije dodeljen
PubChem	6918248
ChemSpider	5293454
UNII	37JK4STR6Z
KEGG	D02577
ChEMBL	CHEMBL231068
Hemijski podaci
Formula	C20H21F3N4O
Mol. masa	390,40 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28) ; Key: PPRRDFIXUUSXRA-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Nije kontrolisan
Način primene	Oralno

Flibanserin (BIMT-17, Girosa) je lek koji je razvila kompanija Beringer Ingelhajm kao nehormonski tretman za žene pre menopoze sa poremećajem hipoaktivne seksualne želje.^[6]^[7] Razvoj je prekinut oktobra 2010, nakon što je FDA objavila negativan izveštaj.^[8]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. (2002). „Pharmacology of flibanserin”. CNS Drug Rev. 8 (2): 117-142. DOI:10.1111/j.1527-3458.2002.tb00219.x. PMID 12177684.
↑ Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L (April 2008). „Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)”. Sexologies 17 (Suppl 1): S133–4. DOI:10.1016/S1158-1360(08)72886-X.
↑ Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)

Vidi još[uredi | uredi kod]

4

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

Vijagra za žene?
Marazziti D, Palego L, Giromella A, et al. (June 2002). „Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain”. Int. J. Neuropsychopharmacol. 5 (2): 131-40. DOI:10.1017/S1461145702002869. PMID 12135537.
Podhorna J, Brown RE (June 2000). „Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety”. Br J Pharmacol 130 (4): 739-746. DOI:10.1038/sj.bjp.0703364. PMC 1572126. PMID 10864879. Arhivirano iz originala na datum 2013-01-06. Pristupljeno 2014-04-05.
Brambilla A, Baschirotto A, Grippa N, Borsini F (December 1999). „Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain”. Eur Neuropsychopharmacol 10 (1): 63-7. DOI:10.1016/S0924-977X(99)00056-5. PMID 10647099.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. (2002). „Pharmacology of flibanserin”. CNS Drug Rev. 8 (2): 117-142. DOI:10.1111/j.1527-3458.2002.tb00219.x. PMID 12177684.

[7] Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L (April 2008). „Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)”. Sexologies 17 (Suppl 1): S133–4. DOI:10.1016/S1158-1360(08)72886-X.

[spon-8] Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Flibanzerin

Reference[uredi | uredi kod]

Vidi još[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga